-
Je něco špatně v tomto záznamu ?
3-Substituted N-Benzylpyrazine-2-carboxamide Derivatives: Synthesis, Antimycobacterial and Antibacterial Evaluation
L. Semelková, O. Janďourek, K. Konečná, P. Paterová, L. Navrátilová, F. Trejtnar, V. Kubíček, J. Kuneš, M. Doležal, J. Zitko,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 1997-01-01
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2009-03-01
Health & Medicine (ProQuest)
od 1997-01-01
- MeSH
- antibakteriální látky chemická syntéza chemie farmakologie MeSH
- buňky Hep G2 MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- molekulární struktura MeSH
- Mycobacterium tuberculosis účinky léků MeSH
- pyraziny chemická syntéza chemie farmakologie MeSH
- simulace molekulového dockingu MeSH
- Staphylococcus aureus účinky léků MeSH
- Staphylococcus epidermidis účinky léků MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
A series of substituted N-benzyl-3-chloropyrazine-2-carboxamides were prepared as positional isomers of 5-chloro and 6-chloro derivatives, prepared previously. During the aminolysis of the acyl chloride, the simultaneous substitution of chlorine with benzylamino moiety gave rise to N-benzyl-3-(benzylamino)pyrazine-2-carboxamides as side products, in some cases. Although not initially planned, the reaction conditions were modified to populate this double substituted series. The final compounds were tested against four mycobacterial strains. N-(2-methylbenzyl)-3-((2-methylbenzyl)amino)pyrazine-2-carboxamide (1a) and N-(3,4-dichlorobenzyl)-3-((3,4-dichlorobenzyl)amino)pyrazine-2-carboxamide (9a) proved to be the most effective against Mycobacterium tuberculosis H37Rv, with MIC = 12.5 μg·mL(-1). Compounds were screened for antibacterial activity. The most active compound was 3-chloro-N-(2-chlorobenzyl)pyrazine-2-carboxamide (5) against Staphylococcus aureus with MIC = 7.81 μM, and Staphylococcus epidermidis with MIC = 15.62 μM. HepG2 in vitro cytotoxicity was evaluated for the most active compounds; however, no significant toxicity was detected. Compound 9a was docked to several conformations of the enoyl-ACP-reductase of Mycobacterium tuberculosis. In some cases, it was capable of H-bond interactions, typical for most of the known inhibitors.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023185
- 003
- CZ-PrNML
- 005
- 20240528081236.0
- 007
- ta
- 008
- 170720s2017 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules22030495 $2 doi
- 035 __
- $a (PubMed)28335571
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Semelková, Lucia $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. semelkol@faf.cuni.cz.
- 245 10
- $a 3-Substituted N-Benzylpyrazine-2-carboxamide Derivatives: Synthesis, Antimycobacterial and Antibacterial Evaluation / $c L. Semelková, O. Janďourek, K. Konečná, P. Paterová, L. Navrátilová, F. Trejtnar, V. Kubíček, J. Kuneš, M. Doležal, J. Zitko,
- 520 9_
- $a A series of substituted N-benzyl-3-chloropyrazine-2-carboxamides were prepared as positional isomers of 5-chloro and 6-chloro derivatives, prepared previously. During the aminolysis of the acyl chloride, the simultaneous substitution of chlorine with benzylamino moiety gave rise to N-benzyl-3-(benzylamino)pyrazine-2-carboxamides as side products, in some cases. Although not initially planned, the reaction conditions were modified to populate this double substituted series. The final compounds were tested against four mycobacterial strains. N-(2-methylbenzyl)-3-((2-methylbenzyl)amino)pyrazine-2-carboxamide (1a) and N-(3,4-dichlorobenzyl)-3-((3,4-dichlorobenzyl)amino)pyrazine-2-carboxamide (9a) proved to be the most effective against Mycobacterium tuberculosis H37Rv, with MIC = 12.5 μg·mL(-1). Compounds were screened for antibacterial activity. The most active compound was 3-chloro-N-(2-chlorobenzyl)pyrazine-2-carboxamide (5) against Staphylococcus aureus with MIC = 7.81 μM, and Staphylococcus epidermidis with MIC = 15.62 μM. HepG2 in vitro cytotoxicity was evaluated for the most active compounds; however, no significant toxicity was detected. Compound 9a was docked to several conformations of the enoyl-ACP-reductase of Mycobacterium tuberculosis. In some cases, it was capable of H-bond interactions, typical for most of the known inhibitors.
- 650 _2
- $a antibakteriální látky $x chemická syntéza $x chemie $x farmakologie $7 D000900
- 650 _2
- $a buňky Hep G2 $7 D056945
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a Mycobacterium tuberculosis $x účinky léků $7 D009169
- 650 _2
- $a pyraziny $x chemická syntéza $x chemie $x farmakologie $7 D011719
- 650 _2
- $a Staphylococcus aureus $x účinky léků $7 D013211
- 650 _2
- $a Staphylococcus epidermidis $x účinky léků $7 D013212
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Janďourek, Ondřej $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. JANDO6AA@faf.cuni.cz.
- 700 1_
- $a Konečná, Klára $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. konecna@faf.cuni.cz.
- 700 1_
- $a Paterová, Pavla $u Department of Clinical Microbiology, University Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic. pavla.paterova@fnhk.cz.
- 700 1_
- $a Navrátilová, Lucie $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. navratl2@faf.cuni.cz.
- 700 1_
- $a Trejtnar, František $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. trejtnarf@faf.cuni.cz.
- 700 1_
- $a Kubíček, Vladimír $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. kubicek@faf.cuni.cz.
- 700 1_
- $a Kuneš, Jiří $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. kunes@faf.cuni.cz.
- 700 1_
- $a Doležal, Martin, $d 1961- $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. dolezalm@faf.cuni.cz. $7 jn19981000714
- 700 1_
- $a Zitko, Jan $u Faculty of Pharmacy in Hradec Králové, Charles University, Heyrovského 1203, 500 05 Hradec Králové, Czech Republic. jan.zitko@faf.cuni.cz.
- 773 0_
- $w MED00180394 $t Molecules $x 1420-3049 $g Roč. 22, č. 3 (2017)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28335571 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20240528081234 $b ABA008
- 999 __
- $a ok $b bmc $g 1238866 $s 984098
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 22 $c 3 $e 20170321 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- LZP __
- $a Pubmed-20170720